botensilimab + gemcitabine + nab-paclitaxel

This is a combination drug regimen consisting of three agents: **botensilimab** (a next-generation anti-CTLA-4 monoclonal antibody immunotherapy), **gemcitabine** (a nucleoside analogue antimetabolite chemotherapeutic), and **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel, a microtubule inhibitor for chemotherapy). This combination is under early to mid-stage clinical investigation for the treatment of advanced solid tumors, most notably metastatic pancreatic cancer. Botensilimab acts as an immune checkpoint inhibitor to enhance T-cell activity; gemcitabine inhibits DNA synthesis in dividing cells; nab-paclitaxel delivers paclitaxel in an albumin-bound (nanoparticle) form to increase drug uptake by tumor cells and avoid solvent-related side effects. The combination aims to synergize immune-mediated anti-tumor activity with two chemotherapeutic agents targeting rapid cell division and promoting tumor cell death. The primary indication under investigation is metastatic pancreatic cancer.

Other names

botensilimabgemcitabinenab-paclitaxelnanoparticle albumin-bound paclitaxel